|
22 Apr 2021 |
Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
|
|
22 Apr 2021 |
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
|
|
22 Apr 2021 |
SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
|
|
21 Apr 2021 |
Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005
|
|
20 Apr 2021 |
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
|
|
20 Apr 2021 |
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
|
|
19 Apr 2021 |
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
|
|
19 Apr 2021 |
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
|
|
19 Apr 2021 |
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer
|
|
19 Apr 2021 |
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
|
|
18 Apr 2021 |
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma, Regardless of PD-L1 Expression Status
|
|
16 Apr 2021 |
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
|
|
16 Apr 2021 |
Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
|
|
16 Apr 2021 |
Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC
|
|
16 Apr 2021 |
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
|
|
15 Apr 2021 |
Merck to Discontinue Development of MK-7110 for COVID-19
|
|
15 Apr 2021 |
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
|
|
15 Apr 2021 |
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
|
|
14 Apr 2021 |
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
|
|
13 Apr 2021 |
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
|
|
13 Apr 2021 |
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
|
|
13 Apr 2021 |
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
|
|
13 Apr 2021 |
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
|
|
12 Apr 2021 |
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021
|
|
12 Apr 2021 |
Shattuck Labs Highlights Preclinical Data for SL-9258 (TIGIT-Fc-LIGHT) in an Acquired Resistance Model and Expanded Preclinical Data from the GADLEN™ Platform at AACR 2021
|
